BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 16, Issue 1
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report
©The Author(s) 2024.
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 234-243
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.234
Table 2 Treatment strategy
Case
1L
2L
3L
4L
Case 1OxaliplatinIrinotecanIrinotecanNA3
Folinic acidFolinic acidFolinic acid
FluorouracilFluorouracilFluorouracil
BevacizumabCetuximabBevacizumab
(7 cycles)(30 cycles)(2 cycles)
Case 2OxaliplatinIrinotecanIrinotecanTrifluridine/tipiracil
CapecitabineFolinic acidFolinic acid
BevacizumabFluorouracilFluorouracil
(4 cycles)BevacizumabCetuximab
(4 cycles)(5 cycles)
Case 3Oxaliplatin
Irinotecan
Trifluridine/tipiracil (8 cycles)Oxaliplatin
Folinic acidFolinic acidFolinic acid
FluorouracilFluorouracilFluorouracil
(8 cycles)Bevacizumab
(30 cycles)
Case 4Oxaliplatin
Irinotecan
Trifluridine/tipiracil (3 cycles)Fluorouracil
Folinic acidFolinic acidBevacizumab
FluorouracilFluorouracil
(23 cycles)Bevacizumab
(12 cycles)
Case 5Oxaliplatin
Irinotecan
Trifluridine/tipiracil (4 cycles)Oxaliplatin
Folinic acidFolinic acidBevacizumab
FluorouracilFluorouracil
(12 cycles)Bevacizumab
(11 cycles)
Case 6Oxaliplatin
Irinotecan
Trifluridine/tipiracil (2 cycles)NA
Folinic acidFolinic acid
FluorouracilFluorouracil
BevacizumabBevacizumab
(7 cycles)(21 cycles)
Case 7Oxaliplatin
Irinotecan
Trifluridine/tipiracil (5 cycles)Oxaliplatin
Folinic acidFolinic acidCapecitabine
FluorouracilFluorouracilBevacizumab
BevacizumabCetuximab
(9 cycles)(16 cycles)
Case 8OxaliplatinOxaliplatinNA1NA
Folinic acidCapecitabine
FluorouracilBevacizumab
Bevacizumab(5 cycles)
(12 cycles)
Case 9OxaliplatinIrinotecanTrifluridine/tipiracil (4 cycles)Oxaliplatin
CapecitabineFolinic acidCapecitabine
BevacizumabFluorouracilBevacizumab
(6 cycles)Bevacizumab
(22 cycles)
Case 10OxaliplatinIrinotecan
Trifluridine/tipiracil (12 cycles)NA
Folinic acidFolinic acid
FluorouracilFluorouracil
BevacizumabBevacizumab
(10 cycles)(7 cycles)
Case 11OxaliplatinIrinotecanNA2NA
CapecitabineFolinic acid
BevacizumabFluorouracil
(25 cycles)Cetuximab
(8 cycles)
1The patient had no conditions to change treatment.
2Stable disease.
3Death. 1L: First line; 2L: Second line; 3L: Third line; 4L: Fourth line; NA: Not applied.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.